Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Eads & Heald Wealth Management

Eads & Heald Wealth Management lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 9.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,236 shares of the medical research company’s stock after selling 2,136 shares during the quarter. Eads & Heald Wealth Management’s holdings in Edwards Lifesciences were worth $1,335,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Manitou Investment Management Ltd. boosted its position in shares of Edwards Lifesciences by 59,280.6% during the third quarter. Manitou Investment Management Ltd. now owns 146,670 shares of the medical research company’s stock worth $9,679,000 after buying an additional 146,423 shares during the period. United Asset Strategies Inc. lifted its stake in Edwards Lifesciences by 4.0% during the 3rd quarter. United Asset Strategies Inc. now owns 159,917 shares of the medical research company’s stock worth $10,553,000 after acquiring an additional 6,129 shares in the last quarter. AustralianSuper Pty Ltd boosted its holdings in Edwards Lifesciences by 17.8% during the 3rd quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock valued at $216,013,000 after acquiring an additional 494,604 shares during the period. HM Payson & Co. grew its position in Edwards Lifesciences by 18.5% in the 3rd quarter. HM Payson & Co. now owns 7,233 shares of the medical research company’s stock valued at $477,000 after acquiring an additional 1,128 shares in the last quarter. Finally, Solidarity Wealth LLC purchased a new stake in Edwards Lifesciences during the third quarter worth about $1,034,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $67.54 on Friday. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm has a market cap of $40.69 billion, a price-to-earnings ratio of 9.75, a PEG ratio of 3.86 and a beta of 1.13. The stock’s 50-day moving average is $67.92 and its two-hundred day moving average is $77.69.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the business posted $0.59 EPS. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. Analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock worth $1,099,238 in the last 90 days. 1.29% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

EW has been the subject of several recent research reports. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. Daiwa Capital Markets raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Canaccord Genuity Group cut their price objective on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Finally, UBS Group lowered their target price on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Tuesday, September 10th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.